9 citations
,
March 1991 in “Endocrinology” This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.
4 citations
,
September 2024 in “BMC Cancer” In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.
September 2025 in “Deleted Journal” This study found that in vitro environments simulating testosterone levels in elderly males, testosterone and its metabolite DHT significantly reduced macrophages' ability to phagocytize MRSA and Pseudomonas aeruginosa, suggesting AR manipulation and inhibiting testosterone-DHT conversion might help fight wound infections in the elderly.
September 2025 in “e-space (Manchester Metropolitan University)” This study found that testosterone and its metabolite DHT reduced macrophage-mediated phagocytosis of bacteria like MRSA and P. aeruginosa in vitro, and blocking testosterone's conversion to DHT improved bacterial clearance, suggesting potential therapeutic strategies for combating wound infections in the elderly.
April 2016 in “The FASEB Journal” This study found that blocking androgen receptors in male rats during the perinatal period led to permanently increased estrogen and ER-a expression in the hypothalamus, affecting sexual preference in adulthood.